comparemela.com

Latest Breaking News On - Clarissa sowemimo coker - Page 8 : comparemela.com

Oxford Cannabinoid Technologies: Phase 1 approval for lead chronic pain drug

Phase 1 approval for lead chronic pain drug Recruitment to start immediately on company s first human trial Oxford Cannabinoid Technologies (OCT) develops.

Oxford Cannabinoid Technologies reaches milestone with phase 1 trial approval for pain relief drug

<iframe src=https://www.youtube.com/embed/Pe1z4VVzelA></iframe>Oxford Cannabinoid Technologies Holdings PLC Clarissa Sowemimo-Coker tells Proactive s Stephen Gunnion that Medicines and. | May 18, 2023

Oxford Cannabinoid rise continues as first clinical trial gets started

Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF) (OTCH) shares rose again after it confirmed recruitment for a phase 1 trial of its lead.

Oxford Cannabinoid Technologies confirms Sowemimo-Coker as permanent CEO

<iframe src=https://www.youtube.com/embed/r0KvbLyxBD0></iframe>Oxford Cannabinoid Technologies Holdings PLC CEO Clarissa Sowemimo-Coker speaks to Proactive after the pharmaceutical group. | April 13, 2023

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.